Steminent Biotherapeutics, Inc.

As of June 30, 2026, Steminent Biotherapeutics, Inc. carries a market capitalization of 6.28B, placing it among publicly traded companies globally. Its enterprise value stands at 5.46B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Steminent Biotherapeutics, Inc. has 80.58M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Steminent Biotherapeutics, Inc. maintains a current ratio of 21.85, meaning it holds 21.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Steminent Biotherapeutics, Inc.'s stock has gained approximately 302.08% over the past 52 weeks. The 50-day moving average sits at 134.68, while the 200-day moving average is 90.84.

As of June 30, 2026, Steminent Biotherapeutics, Inc. holds 891.65M in cash and equivalents against 69.61M in total debt, resulting in a net debt position of -867.53M. Total book value stands at 1.01B, with working capital of 891.22M providing operational flexibility.

Steminent Biotherapeutics, Inc.'s most recent stock split took place on April 29, 2026 with a 983:998 split ratio.